- Home
- AUPH vs APLT Comparison
AUPH vs APLT Comparison
Compare AUPH & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUPH | APLT |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 38.1M |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AUPH | APLT |
|---|---|---|
| Price | $16.17 | $0.13 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $17.25 | $1.25 |
| AVG Volume (30 Days) | 1.4M | ★ 8.7M |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $265,808,000.00 | $1,000,000.00 |
| Revenue This Year | $21.22 | $124.18 |
| Revenue Next Year | $15.40 | $66.67 |
| P/E Ratio | $28.92 | ★ N/A |
| Revenue Growth | ★ 20.62 | N/A |
| 52 Week Low | $6.55 | $0.10 |
| 52 Week High | $16.48 | $1.50 |
Technical Indicators
Market Signals| Indicator | AUPH | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 62.79 | 27.06 |
| Support Level | $15.57 | $0.10 |
| Resistance Level | $16.07 | $0.13 |
| Average True Range (ATR) | 0.49 | 0.02 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 85.29 | 17.28 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.